{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:04:14Z","timestamp":1783015454934,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diarrhea is a common adverse event of fluoropyrimidine-based chemotherapy. However, limited data are available on the frequency and risk factors of complicated chemotherapy-induced diarrhea (CID) and small intestinal mucosal damage. In this current study, we aimed to determine the incidence of complicated CID and mucosal injury among patients with complicated CID receiving fluoropyrimidine via small bowel capsule endoscopy (CE) and determined baseline risk factors associated with complicated CID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 536 patients with advanced or recurrent gastrointestinal cancer who received fluoropyrimidine-based chemotherapy were retrospectively analyzed. Diarrhea was evaluated using the Common Terminology Criteria for Adverse Events version 4. Complicated CID was defined according to the American Society of Clinical Oncology guidelines. To evaluate small intestinal mucosal injury in patients with complicated CID, CE was performed. Multivariate analysis was performed to identify risk factors for complicated CID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total number of 32 (6%) patients developed complicated CID. Complicating symptoms were noted in 25 (78%) patients, with cramping, vomiting, and sepsis being observed in 15 (60%), 8 (32%), and 3 (12%) patients, respectively. Among the 13 patients who underwent CE, 11 (85%) showed abnormal findings. Multivariate analysis revealed that oral fluoropyrimidine administration was a risk factor for complicated CID (odds ratio 2.95; 95% confidence interval 1.06\u20138.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the relatively low incidence of complicated CID, mucosal injury of small intestine was common in patients with complicated fluoropyrimidine-induced diarrhea and oral fluoropyrimidine was an independent risk factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01507-5","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T08:05:57Z","timestamp":1603785957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea"],"prefix":"10.1186","volume":"20","author":[{"given":"Miho","family":"Sakumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohachi","family":"Nanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"issue":"18","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14(13):1278\u201386.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.1994.12.1.14","volume":"12","author":"TR Buroker","year":"1994","unstructured":"Buroker TR, O\u2019Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol . 1994;12(1):14\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"A Stein","year":"2010","unstructured":"Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51\u201363.","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","volume":"26","author":"DG Haller","year":"2008","unstructured":"Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26(13):2118\u201323.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10(11):1063\u20139.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2169\/internalmedicine.55.5800","volume":"55","author":"A Hosokawa","year":"2016","unstructured":"Hosokawa A, Nishikawa J, Ando T, Sugiyama T. Chemotherapy-induced Small Bowel Injury. Intern Med. 2016;55(8):1023.","journal-title":"Intern Med"},{"issue":"7","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1129::AID-CNCR5>3.0.CO;2-4","volume":"86","author":"F Fata","year":"1999","unstructured":"Fata F, Ron IG, Kemeny N, O\u2019Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999;86(7):1129\u201334.","journal-title":"Cancer"},{"issue":"14","key":"1507_CR9","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson 3rd","year":"2004","unstructured":"Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O\u2019Dorisio TM, Vokes EE, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol . 2004;22(14):2918\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44\u201370.","journal-title":"Ann Oncol"},{"key":"1507_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","volume":"30","author":"K Muro","year":"2018","unstructured":"Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2018;30:19\u201333.","journal-title":"Ann Oncol"},{"issue":"1","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2005.00442.x","volume":"75","author":"M Gorschluter","year":"2005","unstructured":"Gorschluter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IG, Sauerbruch T, Glasmacher A. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1\u201313.","journal-title":"Eur J Haematol"},{"issue":"5","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/den.13346","volume":"31","author":"N Hosoe","year":"2019","unstructured":"Hosoe N, Takabayashi K, Ogata H, Kanai T. Capsule endoscopy for small-intestinal disorders: current status. Dig Endosc. 2019;31(5):498\u2013507.","journal-title":"Dig Endosc"},{"issue":"10","key":"1507_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1055\/s-2005-870329","volume":"37","author":"LY Korman","year":"2005","unstructured":"Korman LY, Delvaux M, Gay G, Hagenmuller F, Keuchel M, Friedman S, Weinstein M, Shetzline M, Cave D, de Franchis R. Capsule endoscopy structured terminology (CEST): proposal of a standardized and structured terminology for reporting capsule endoscopy procedures. Endoscopy. 2005;37(10):951\u20139.","journal-title":"Endoscopy"},{"issue":"5","key":"1507_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/j.gastro.2005.03.020","volume":"128","author":"L Maiden","year":"2005","unstructured":"Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128(5):1172\u20138.","journal-title":"Gastroenterology"},{"issue":"10","key":"1507_CR16","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","volume":"15","author":"J Andreyev","year":"2014","unstructured":"Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447\u201360.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3748\/wjg.v23.i1.42","volume":"23","author":"FG Rodrigues","year":"2017","unstructured":"Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. World J Gastroenterol. 2017;23(1):42\u20137.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1507_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s005209900085","volume":"8","author":"S Cascinu","year":"2000","unstructured":"Cascinu S, Bichisao E, Amadori D, Silingardi V, Giordani P, Sansoni E, Luppi G, Catalano V, Agostinelli R, Catalano G. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer. 2000;8(1):65\u20137.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.1993.11.1.148","volume":"11","author":"S Cascinu","year":"1993","unstructured":"Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol . 1993;11(1):148\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00280-008-0732-8","volume":"63","author":"RM Logan","year":"2009","unstructured":"Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol. 2009;63(2):239\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"e31808","DOI":"10.1371\/journal.pone.0031808","volume":"7","author":"CT Chang","year":"2012","unstructured":"Chang CT, Ho TY, Lin H, Liang JA, Huang HC, Li CC, Lo HY, Wu SL, Huang YF, Hsiang CY. 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappaB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS ONE. 2012;7(3):e31808.","journal-title":"PLoS ONE"},{"issue":"14","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3748\/wjg.v20.i14.3751","volume":"20","author":"CS Lee","year":"2014","unstructured":"Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol. 2014;20(14):3751\u201361.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MEG.0000000000000828","volume":"29","author":"MP Dore","year":"2017","unstructured":"Dore MP, Pes GM, Murino A, Quarta Colosso B, Pennazio M. Short article: Small intestinal mucosal injury in patients taking chemotherapeutic agents for solid cancers. Eur J Gastroenterol Hepatol. 2017;29(5):568\u201371.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/00365521.2019.1575466","volume":"54","author":"K Ota","year":"2019","unstructured":"Ota K, Takeuchi T, Kojima Y, Harada S, Ozaki H, Sugawara N, Hirata Y, Yamaguchi T, Terazawa T, Kakimoto K, et al. Fluoropyrimidine-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea. Scand J Gastroenterol. 2019;54(2):227\u201332.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"1507_CR25","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0959-8049(98)00259-7","volume":"34","author":"J Zalcberg","year":"1998","unstructured":"Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number Tomudex. International Study Group. Eur J Cancer. 1998;34(12):1871\u20135.","journal-title":"Eur J Cancer"},{"issue":"15","key":"1507_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/jnci\/94.15.1160","volume":"94","author":"AD McCollum","year":"2002","unstructured":"McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94(15):1160\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2004.07.121","volume":"22","author":"JA Meyerhardt","year":"2004","unstructured":"Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O\u2019Connell MJ, Mayer RJ, Cummings B, Willett C, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol . 2004;22(4):648\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1507_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14740338.2016.1105959","volume":"15","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O, ElHalawani H, Essam-Eldin S. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opin Drug Saf. 2016;15(1):5\u201320.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1507_CR29","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1038\/s41598-017-07750-3","volume":"7","author":"E Ter Veer","year":"2017","unstructured":"Ter Veer E, Ngai LL, Valkenhoef GV, Mohammad NH, Anderegg MCJ, van Oijen MGH, van Laarhoven HWM. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: a network meta-analysis. Sci Rep. 2017;7(1):7142.","journal-title":"Sci Rep"},{"issue":"5","key":"1507_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6601224","volume":"89","author":"Y Yamada","year":"2003","unstructured":"Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer. 2003;89(5):816\u201320.","journal-title":"Br J Cancer"},{"issue":"15","key":"1507_CR31","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-04-0469","volume":"10","author":"QS Chu","year":"2004","unstructured":"Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004;10(15):4913\u201321.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1507_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81(1):47\u201351.","journal-title":"J Clin Invest"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01507-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T19:18:42Z","timestamp":1635275922000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01507-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.24610\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.24610\/v2","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"1 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study included a waiver and did not require written informed consent, which was approved by the Institutional Board Review (Toyama University Hospital Review Committee: 27-74).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}